Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tertomotide - KAEL-GemVax

Drug Profile

Tertomotide - KAEL-GemVax

Alternative Names: GV1001®; hTERT RNA vaccine - KAEL-GemVax; LucaVax; Telomerase peptide vaccine - KAEL-GemVax; TeloVac

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Cancer vaccines; Peptide fragments; Ribonucleoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Alzheimer's disease; Benign prostatic hyperplasia; Colorectal cancer; Non-small cell lung cancer
  • Phase I/II Malignant melanoma
  • No development reported Solid tumours
  • Discontinued Liver cancer

Most Recent Events

  • 22 May 2019 Kael GemVax plans a phase IIa trial for Alzheimer's Disease (SC) in September 2019 (NCT03959553)
  • 03 May 2019 US FDA approves IND application for tertomotide in Alzheimer’s disease
  • 05 Apr 2019 The Ministry of Food and Drug Safety approves IND application for phase III trial in Benign Prostatic Hyperplasia in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top